The Importance of Using SGLT-2 Inhibitors in Heart Failure: An Updated Review
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT-2i) have emerged as revolutionary therapeutic agents in the management of heart failure, regardless of the presence of diabetes mellitus.Originally developed for glycemic control, SGLT-2 inhibitors have shown significant benefits in reducing heart failure hospitalizations and cardiovascular mortality.These effects extend to patients with both reduced and preserved ejection fraction.The mechanisms of action are diverse and include the reduction of oxidative stress, modulation of volume overload, and metabolic cardioprotective effects, as well as improved renal function.High-impact studies, such as the EMPA-REG, DAPA-HF, and EMPEROR-Reduced clinical trials, reinforce the efficacy and safety of this drug class, consolidating its role in current heart failure treatment guidelines.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.